Telix Advances ProstACT Phase 3 Trial with First Patient Dosed in Global Expansion

• First patient dosed in Part 2 of ProstACT Global Phase 3 trial
• Trial evaluates TLX591 combined with standard of care in metastatic castration resistant prostate cancer
• Global expansion includes Australia, New Zealand, Canada, and planned sites in US, China, Japan, and Europe
• Preliminary Part 1 data to be submitted to FDA and EMA for regulatory engagement